Anavex Life Sciences Corp.
AVXL· Nasdaq
Filed Feb 9, 2022 · 10-Q · 40 days after period end · 0001731122-22-000196
| Metric | Q1 2022 | Q1 2021 | Q1 2020 | Q1 2019 |
|---|---|---|---|---|
| Net Income | -$10.88M | -$7.86M | -$6.59M | -$6.92M |
| EPS Diluted | -$0.14 | -$0.12 | -$0.12 | -$0.15 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anavex Life Sciences Corp. · CIK 1314052 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Feb 9, 2022 · 40 d after period end